The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer
详细信息 查看全文
- 作者：Husam Abdel-Qadira ; b ; c ; d ; Eitan Amira ; c ; e ; Hadas D. Fischerb ; Longdi Fub ; Peter C. Austinb ; c ; Paula J. Harveya ; d ; f ; g ; Paula A. Rochona ; b ; c ; d ; f ; Douglas S. Leea ; b ; c ; g ; 1 ; Geoffrey M. Andersonb ; c ; f ; 1 ; geoff.anderson@utoronto.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：Hormonal therapy ; Endocrine therapy ; Anastrozole ; Letrozole ; Exemestane ; Coronary artery disease ; Cardio-oncology ; Survivorship
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：68
- 期：Complete
- 页码：11-21
- 全文大小：747 K
文摘
- •
Aromatase inhibitors and tamoxifen are used to treat post-menopausal breast cancer.
- •
We studied the myocardial infarction risk of aromatase inhibitors and tamoxifen.
- •
This was an observational cohort study in the Canadian province of Ontario.
- •
Measured baseline differences were adjusted using propensity score-based methods.
- •
Aromatase inhibitors were associated with a higher risk of myocardial infarction.